Nitisinone MDK is a pharmaceutical medication primarily used in the treatment of hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder that affects the metabolism of the amino acid tyrosine. By inhibiting the enzyme 4-hydroxyphenylpyruvate dioxygenase, Nitisinone MDK reduces the formation of harmful substances in the body, thereby preventing liver and kidney damage, and reducing the risk of liver cancer in patients with HT-1. It is available in various forms, including tablets and oral suspension, making it accessible for patients of different ages and preferences. As with any medication, it is important to use Nitisinone MDK under the guidance of a healthcare professional to ensure proper dosage and to monitor for any potential side effects.